** Shares of Neurotech International NTI.AX rise as much as 10.6% to A$0.073, posting their biggest intraday percentage gain since Aug. 14
** Stock hits its highest level since Sept. 9
** Biopharmaceutical co says the U.S. Food and Drug Administration granted the orphan drug status to its NTI164 drug, aimed at treating Rett Syndrome
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** About 1.6 mln shares change hands, compared with the 30-day average volume of around 601,000
** Stock up 1.5% YTD, including session's move
(Reporting by Aaditya Govind Rao in Bengaluru)
((Aaditya.govindrao@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。